Understand the source comparison
Does Dihexa Cause Side Effects in Studies?: Comparison of Nootropic Peptide Safety Profiles
Dihexa HGF/c-Met potentiation → BDNF upregulation Reduced locomotor activity at ≥10mg/kg; no organ toxicity at research doses (0.01–0.1mg/kg) None. No human trials completed as of 2026 Exceptionally clean rodent profile, but absence of human data is the critic
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF/c-Met potentiation → BDNF upregulation
- Reduced locomotor activity at ≥10mg/kg; no organ toxicity at research doses (0.01–0.1mg/kg)
- None. No human trials completed as of 2026
- Exceptionally clean rodent profile, but absence of human data is the critical constraint. Cannot assume translatability
- Semax
- BDNF mimetic, ACTH fragment analogue
- Mild transient hypertension in some rodent models; rare reports of anxiety in anecdotal human use
- Limited. Small Russian clinical trials show general tolerability but lack rigorous Phase III validation
- Moderate human exposure suggests acceptable tolerability, but data quality and sample sizes remain weak
- Cerebrolysin
- Porcine brain-derived peptide mixture
- Injection site reactions common; headache and dizziness reported in clinical use
- Extensive. Used clinically in Europe and Asia for stroke recovery
- Well-characterised human safety profile, though allergic reactions to animal-derived proteins occur
- P21 (Cerebrolysin tetrapeptide)
- CNTF fragment, neuroprotective signalling
- Minimal adverse effects in rodent models at cognitive doses
- None. Remains purely investigational
- Similar mechanistic class to dihexa but less potent; likely comparable safety margin
- Noopept
- AMPA modulator, neuropeptide analogue
- Irritability and sleep disturbances at high doses; generally well-tolerated in rodent and small human trials
- Limited human trials in Russia; widely used in nootropic communities
- Moderate human exposure with acceptable tolerability, but large-scale trials absent